Last updated: September 24, 2026
Solifenacin succinate is a mature, genericized antimuscarinic drug used for overactive bladder and, in selected markets, pediatric neurogenic detrusor overactivity. The core 5 mg and 10 mg immediate-release tablet market is price competitive, so commercial opportunity depends on formulation differentiation rather than basic active-ingredient exclusivity. The strongest opportunities are pediatric liquid products, orally disintegrating tablets, lactose-free and low-pill-burden products, combination therapies, and supply-efficient generic platforms.
What is solifenacin succinate used for?
Solifenacin succinate is the succinate salt of solifenacin, a selective muscarinic M3 receptor antagonist. It reduces urinary urgency, frequency, and urge urinary incontinence associated with overactive bladder.
The principal branded product is Vesicare, marketed by Astellas Pharma. The usual adult doses are:
| Product |
Strength |
Dosage form |
Main use |
| Vesicare |
5 mg, 10 mg |
Film-coated tablet |
Overactive bladder |
| Vesicare LS |
1 mg/mL |
Oral suspension |
Pediatric neurogenic detrusor overactivity |
| Generic solifenacin succinate |
5 mg, 10 mg |
Film-coated tablet |
Overactive bladder |
The FDA approved Vesicare in 2004 and later approved Vesicare LS for pediatric patients with neurogenic detrusor overactivity. Solifenacin is a small molecule, so biosimilar regulation does not apply. Competition occurs through abbreviated new drug applications, 505(b)(2) products, regional hybrid applications, and reformulated products rather than through the biosimilar pathway (FDA, 2004; FDA, 2020).
What excipients are used in solifenacin succinate tablets?
The reference tablet uses a conventional immediate-release excipient system. Public labeling identifies lactose monohydrate, corn starch, hypromellose, and magnesium stearate in the tablet core. The film coat contains hypromellose, talc, macrogol, titanium dioxide, and iron oxides used for color differentiation (FDA, 2023).
Reference formulation architecture
| Formulation function |
Common excipient approach |
Commercial purpose |
| Diluent |
Lactose monohydrate |
Provides tablet mass and improves compression |
| Binder or disintegrant |
Corn starch |
Supports granulation and breakup |
| Lubricant |
Magnesium stearate |
Reduces ejection force |
| Film former |
Hypromellose |
Protects the core and improves appearance |
| Plasticizer |
Macrogol or polyethylene glycol |
Improves coating flexibility |
| Opacifier |
Titanium dioxide |
Controls opacity and appearance |
| Colorant |
Iron oxides |
Differentiates 5 mg and 10 mg strengths |
| Anti-tacking agent |
Talc |
Improves coating performance |
The low dose of active ingredient creates a formulation-development issue. A 5 mg tablet contains a small drug load relative to the total tablet mass. Blend uniformity, segregation control, and content uniformity are therefore more important than the nominal dose alone.
Which excipient strategy is best for generic solifenacin tablets?
A conventional lactose-starch direct-compression or wet-granulation platform is commercially efficient for a standard generic. The formulation should prioritize content uniformity, rapid disintegration, low friability, and reproducible dissolution across the 5 mg and 10 mg strengths.
Direct compression
Direct compression can reduce manufacturing steps and lower cost. It requires excipients with reliable flow and compactibility, such as microcrystalline cellulose, spray-dried lactose, crospovidone, or coprocessed filler systems.
The main risks are poor low-dose content uniformity, segregation during transfer, and sensitivity to lubricant overmixing. These risks can be reduced through ordered blending, controlled particle-size distribution, and validated blend sampling.
Wet granulation
Wet granulation can improve uniformity and flow when the active ingredient or excipient blend has poor handling properties. It increases process complexity and introduces drying and residual-moisture controls.
A wet-granulated formulation may be preferable when:
- The active ingredient segregates from the diluent.
- Tablet weight is low.
- Compression causes capping or lamination.
- Dissolution varies between manufacturing lots.
- The sponsor wants to retain a lactose-based platform but improve manufacturability.
Coated-tablet design
The film coat should protect the tablet without delaying immediate release. Excessive coating weight, high polymer viscosity, or over-drying can slow disintegration and dissolution.
A lower-cost generic can use a standard hypromellose-based coat. A premium product can differentiate through:
- Improved color stability.
- Reduced coating weight.
- Opacifier reduction.
- Titanium-dioxide-free color systems.
- Moisture-barrier coatings.
- Distinctive strength identification for adherence.
Any coating change must preserve comparative dissolution and demonstrate acceptable stability.
What formulation patents protect solifenacin succinate products?
The original solifenacin compound and product protection has expired in the United States. The key historical U.S. patent associated with Vesicare was U.S. Patent No. 6,017,927, assigned to Yamanouchi Pharmaceutical, now part of Astellas. The patent covered solifenacin-related compounds and supported the branded product’s original exclusivity.
The patent term was extended beyond the ordinary statutory term, with U.S. protection historically extending into 2020. Pediatric exclusivity associated with the Vesicare program added a limited period after the underlying patent and regulatory exclusivity period. The commercial consequence is that ordinary tablet generic competition is now established.
Current formulation strategy should distinguish between:
- Expired compound and original-product protection.
- Potentially active patents on later liquid, pediatric, combination, device, or manufacturing products.
- Market-specific patents outside the United States.
- Regulatory exclusivity that is separate from patent rights.
A sponsor should not assume that an expired compound patent clears every dosage form. A suspension, orally disintegrating tablet, fixed-dose combination, or modified-release product may have separate formulation or method-of-use claims.
When did solifenacin succinate lose exclusivity?
U.S. exclusivity was lost in stages.
| Milestone |
Approximate timing |
Commercial effect |
| Vesicare FDA approval |
2004 |
Originator launch |
| First generic litigation and ANDA activity |
2010s |
Paragraph IV and patent-certification activity |
| Original U.S. patent protection |
Through approximately 2020 |
Delayed unrestricted generic entry |
| Vesicare LS approval |
2020 |
Separate pediatric liquid opportunity |
| Broad generic tablet competition |
2020 onward |
Price compression in 5 mg and 10 mg tablets |
The exact launch date for each generic depends on settlement terms, authorized-generic activity, regulatory approval, and the applicant’s commercial decision. Generic entry is therefore product-specific rather than determined solely by the earliest patent expiration.
What was the Paragraph IV and litigation history?
Solifenacin succinate was subject to the standard ANDA patent-challenge framework. Applicants could certify that listed patents were expired, were not infringed, were invalid, or would not be infringed by the proposed generic.
Public litigation records and FDA patent listings should be reviewed by applicant and dosage form because the relevant disputes evolved over time. The important commercial point is that the central compound and original tablet estate no longer blocks ordinary U.S. generic development.
Litigation implications for new entrants
A current entrant faces more risk from product design and regulatory execution than from the original compound patent. Relevant issues include:
- Whether the proposed product is an ordinary tablet or a distinct dosage form.
- Whether a liquid product implicates later pediatric formulation claims.
- Whether a combination product raises new method-of-use claims.
- Whether manufacturing processes are covered by unexpired patents.
- Whether the applicant can support a suitable bioequivalence or comparative dissolution package.
The absence of a blocking compound patent does not remove the possibility of formulation-specific litigation.
What formulation opportunities exist for solifenacin succinate?
Pediatric oral suspension
The most defensible differentiation opportunity is a stable, palatable oral liquid. Vesicare LS established a pediatric formulation for neurogenic detrusor overactivity. A competing product could pursue a generic or alternative regulatory route, subject to the applicable reference-product and patent requirements.
Critical excipient decisions include:
- Suspending agents such as hypromellose, xanthan gum, or microcrystalline cellulose-based systems.
- Sweeteners such as sucralose, sorbitol, or sucrose.
- Flavor systems with low bitterness and acceptable aftertaste.
- Preservatives where multidose packaging requires them.
- Buffer capacity and pH control.
- Container compatibility and dose-delivery accuracy.
Solifenacin is bitter, and pediatric acceptability can determine adherence. Taste masking should not materially delay absorption or create dose nonuniformity after storage.
Orally disintegrating tablets
An orally disintegrating tablet could address swallowing difficulty among older adults with overactive bladder. A low-dose ODT requires careful control of:
- Drug distribution across the blend.
- Tablet friability.
- Mouthfeel.
- Disintegration time.
- Moisture sensitivity.
- Packaging barrier performance.
Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and flavor systems are common platform choices. The commercial value is higher than that of a standard generic only if the product obtains meaningful channel access, payer coverage, or adherence improvement.
Lactose-free tablets
A lactose-free product can target patients with excipient restrictions and institutional buyers seeking simplified formularies. The opportunity is commercially modest because lactose intolerance does not always require lactose-free medication, but a lactose-free claim can support pharmacy differentiation.
Microcrystalline cellulose, dibasic calcium phosphate, mannitol, or starch-based diluents can replace lactose. Calcium phosphate may improve hardness but can alter dissolution and mouthfeel.
Combination products
Solifenacin has commercial relevance in combination therapy with tamsulosin for men with lower urinary tract symptoms and storage symptoms. The European product Vesomni combines solifenacin and tamsulosin modified release. A combination product requires independent control of each active ingredient’s release profile and may face method-of-use, formulation, and regional patent barriers.
Combination development has greater commercial upside than a fifth conventional 5 mg tablet, but it also requires more complex clinical, regulatory, and manufacturing work.
What manufacturing and intellectual-property barriers exist?
The principal manufacturing barriers are low-dose uniformity, dissolution reproducibility, coating control, and stability. The active ingredient is not generally protected by a live U.S. compound patent, but process know-how can still affect cost and quality.
Potential manufacturing advantages include:
- A low-step direct-compression process.
- Common excipient use across 5 mg and 10 mg strengths.
- A single coating platform with color adjustment.
- High-speed compression with robust weight control.
- Packaging that limits moisture uptake without excessive cost.
- A suspension process with controlled particle size and sedimentation behavior.
Geographic coverage must be assessed country by country. European, Japanese, Canadian, and emerging-market patent registers can contain different expiry dates, supplementary protection rights, pediatric extensions, or formulation claims. A U.S. clearance position does not establish freedom to operate in Europe or Asia.
How strong is the solifenacin patent estate?
The patent estate is weak for ordinary U.S. immediate-release tablets and stronger for differentiated dosage forms.
| Product concept |
Patent position |
Commercial assessment |
| Standard 5 mg tablet |
Compound protection expired |
Highly competitive |
| Standard 10 mg tablet |
Compound protection expired |
Highly competitive |
| Pediatric oral suspension |
Later product and formulation issues may apply |
Higher differentiation |
| Orally disintegrating tablet |
Potential formulation claims |
Moderate opportunity |
| Tamsulosin combination |
Formulation and method-of-use exposure |
More complex |
| Modified-release product |
Technical and patent risk |
Potentially differentiated |
| New manufacturing process |
Process patent or trade-secret exposure |
Cost advantage possible |
Patent strength should be judged by claim scope, remaining term, enforceability, regulatory linkage, and the number of viable non-infringing formulation alternatives. For standard tablets, competitive strength depends more on manufacturing economics and supply reliability than on patent barriers.
What is the FDA regulatory and Orange Book status?
Vesicare is an FDA-approved prescription product, and solifenacin succinate tablets are available through ANDA-approved generic products. The FDA Orange Book is the controlling source for listed patents, exclusivity, therapeutic equivalence codes, and current reference-product information (FDA, 2024).
The commercial regulatory pathway is usually:
- ANDA for a conventional 5 mg or 10 mg tablet.
- Demonstration of pharmaceutical equivalence.
- Bioequivalence against the reference product.
- Patent certification under Section viii, Paragraph III, or Paragraph IV, as applicable.
- FDA approval subject to the applicant’s patent and exclusivity position.
A 505(b)(2) pathway may be relevant for a new suspension, ODT, combination, or other product that cannot rely entirely on the generic tablet reference. The pathway can support differentiation but usually requires more clinical and regulatory work.
Which commercial opportunities remain?
The highest-value opportunities are differentiated products with a clear patient or channel benefit.
| Opportunity |
Development burden |
Margin potential |
Main risk |
| Standard generic tablet |
Low to moderate |
Low |
Price erosion |
| Lactose-free tablet |
Low |
Low to moderate |
Limited willingness to pay |
| ODT |
Moderate |
Moderate |
Taste and stability |
| Pediatric suspension |
Moderate to high |
Moderate to high |
Patent, palatability, supply |
| Fixed-dose combination |
High |
High |
Clinical and formulation complexity |
| Regional licensing |
Variable |
Moderate |
Market access and local rights |
| Contract manufacturing |
Moderate |
Low to moderate |
Customer concentration |
Licensing opportunities are more likely to involve regional rights, pediatric products, specialty generics, or combination products than the basic active ingredient. Originator licensing has limited value for standard tablets because the core market is already genericized.
Revenue exposure for Astellas is concentrated in the mature Vesicare franchise and is structurally reduced by generic competition. For generic manufacturers, the market can still be attractive where procurement is fragmented, supply reliability is poor, or differentiated presentations command a premium.
What generic launch scenarios exist?
Three launch scenarios are commercially realistic:
- Commodity launch: A conventional 5 mg and 10 mg tablet enters through an ANDA and competes primarily on price and supply.
- Value-added launch: A lactose-free, ODT, or improved packaging configuration targets pharmacies, long-term-care providers, or patients with swallowing barriers.
- Specialty launch: A pediatric suspension or combination product targets a narrower population with higher development and regulatory barriers.
The commodity scenario has the fastest path but the lowest margin. The specialty scenario offers stronger defensibility but requires a larger evidence package and more complex freedom-to-operate analysis.
Key Takeaways
- Solifenacin succinate tablets are mature generic products with limited remaining U.S. compound-patent protection.
- Standard 5 mg and 10 mg tablets are primarily manufacturing and pricing businesses.
- The most relevant excipient controls are low-dose blend uniformity, rapid disintegration, coating performance, and stability.
- Pediatric oral suspension is the clearest differentiated formulation opportunity.
- ODT, lactose-free, and adherence-focused products offer secondary opportunities.
- Combination products can produce greater value but carry higher regulatory and patent risk.
- Solifenacin is a small molecule, so biosimilar competition is not applicable.
- The FDA Orange Book and jurisdiction-specific patent registers should govern product clearance decisions.
- Geographic patent positions can differ materially from the U.S. position.
- Commercial success depends more on formulation differentiation, supply reliability, and channel access than on the expired originator compound patent.
FAQs
Is solifenacin succinate suitable for an orally disintegrating tablet?
Yes. Its low dose is compatible with ODT development, but content uniformity, bitterness, friability, moisture sensitivity, and rapid dissolution require focused formulation work.
Can lactose be removed from solifenacin succinate tablets?
Yes. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, and starch-based systems can replace lactose, subject to dissolution, compression, stability, and bioequivalence testing.
Is solifenacin succinate a good candidate for a pediatric liquid?
Yes. Pediatric liquid development has a clear clinical rationale, but taste masking, suspension uniformity, preservative selection, dosing accuracy, and formulation-specific patent review are central risks.
Does solifenacin succinate have biosimilar competition?
No. Solifenacin succinate is a chemically synthesized small molecule. Competition proceeds through generic and hybrid-drug pathways rather than biosimilar approval.
What is the best commercial strategy for a new solifenacin product?
A standard tablet is the lowest-risk route but has limited margin potential. A pediatric suspension, ODT, or combination product offers better differentiation if the sponsor can support the required regulatory, manufacturing, and patent analysis.
References
- Astellas Pharma Inc. (2023). Vesicare prescribing information.
- European Medicines Agency. (2023). Vesomni: EPAR product information.
- Food and Drug Administration. (2004). FDA approves Vesicare for overactive bladder.
- Food and Drug Administration. (2020). Vesicare LS approval and prescribing information.
- Food and Drug Administration. (2023). Vesicare tablets prescribing information.
- Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- United States Patent and Trademark Office. (2000). U.S. Patent No. 6,017,927, Quinuclidine derivatives.
